Umeclidinium bromide
Umeclidinium bromide
Umeclidinium bromide (pronounced as yoo mek li DIN ee um BROE mide) is a long-acting muscarinic antagonist (LAMA) used in the management of chronic obstructive pulmonary disease (COPD). It is marketed under the brand name Incruse Ellipta among others.
Etymology
The name "Umeclidinium bromide" is derived from its chemical structure. "Umeclidinium" is a combination of parts of the names of its chemical constituents, and "bromide" refers to the bromine atom present in the compound.
Pharmacology
Umeclidinium bromide is a bronchodilator that works by relaxing the muscles in the airways and increasing the flow of air to the lungs. It is a type of drug known as a long-acting muscarinic antagonist (LAMA), which blocks the action of acetylcholine, a neurotransmitter that can cause the airways to constrict.
Usage
Umeclidinium bromide is used as a maintenance treatment for chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is not used to relieve sudden breathing problems and will not replace a rescue inhaler.
Side Effects
Common side effects of Umeclidinium bromide include upper respiratory tract infection, stuffy or runny nose, cough, mouth or throat pain, joint pain, changes in your voice, and constipation. Serious side effects may include allergic reactions, urinary retention, and worsening of narrow-angle glaucoma.
Related Terms
- Chronic obstructive pulmonary disease (COPD)
- Bronchodilator
- Muscarinic antagonist
- Acetylcholine
- Incruse Ellipta
External links
- Medical encyclopedia article on Umeclidinium bromide
- Wikipedia's article - Umeclidinium bromide
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski